Details of the Drug Combinations

General Information of This Drug (ID: DM2NLS9)

• Drug Name: Ciprofloxacin XR (DM2NLS9)
• Synonyms: ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy

Indication

Acute gonococcal cervicitis; ICD 11: N.A.; Status: Approved [1]; Acute maxillary sinusitis; ICD 11: N.A.; Status: Approved [1]; Anthrax; ICD 11: 1B97; Status: Approved [1]; Bacillary dysentery; ICD 11: 1A02; Status: Approved [1]; Bacterial infection; ICD 11: 1A00-1C4Z; Status: Approved [2]; Chancroid; ICD 11: N.A.; Status: Approved [1]; Crohn disease; ICD 11: DD70; Status: Approved [1]; Cystitis; ICD 11: GC00; Status: Approved [1]; Fever; ICD 11: MG26; Status: Approved [1]; Gram-positive bacterial infection; ICD 11: 1B74-1G40; Status: Approved [3]; Inflammation; ICD 11: 1A00-CA43.1; Status: Approved [1]; Malignant otitis externa caused by Pseudomonas aeruginosa; ICD 11: N.A.; Status: Approved [1]; Prostatitis; ICD 11: N.A.; Status: Approved [4]; Staphylococcus aureus infection; ICD 11: N.A.; Status: Approved [1]; Traveler's diarrhea; ICD 11: ME05.1; Status: Approved [1]; Cystic fibrosis; ICD 11: CA25; Status: Phase 2 [5]; Biliary cancer; ICD 11: 2E92.7; Status: Phase 1 [6]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

14 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ciprofloxacin XR + Lumacaftor	DCI59ZK	Lumacaftor	Cystic Fibrosis	[7]
Ciprofloxacin XR + Metronidazole	DC3UJLN	Metronidazole	Crohn's Disease	[8]
Ciprofloxacin XR + Ceftriaxone	DC4Z8NL	Ceftriaxone	Gonococcal Infection	[9]
Ciprofloxacin XR + Ceftriaxone	DCIKDQ8	Ceftriaxone	Gonococcal Infection	[10]
Ciprofloxacin XR + Doxycycline	DCA3SJX	Doxycycline	Diabetic Foot Ulcers	[11]
Ciprofloxacin XR + Etoposide	DCAO7UV	Etoposide	Leukemia	[12]
Ciprofloxacin XR + Celecoxib	DCID9QN	Celecoxib	Pharmacokinetics	[13]
Ciprofloxacin XR + Doxycycline	DCKLMVK	Doxycycline	Rhinoscleroma	[14]
Ciprofloxacin XR + Ivacaftor	DCSUHW4	Ivacaftor	Cystic Fibrosis	[15]
Ofloxacin + Ciprofloxacin XR	DCZQP3K	Ofloxacin	Infection	[16]
Ciprofloxacin XR + Ceftriaxone	DCA04R0	Ceftriaxone	Gonorrhea Male	[17]
Ciprofloxacin XR + Doxycycline	DCTTCKY	Doxycycline	Crohn's Disease	[18]
Ciprofloxacin XR + Rifaximin	DCRVLWR	Rifaximin	Crohn Disease	[19]
Ciprofloxacin XR + Streptomycin	DC9SER2	Streptomycin	Plague, Bubonic	[20]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dexamethasone + Ciprofloxacin XR	DCHM289	Dexamethasone	Otitis externa; Acute otitis media	[21]

References

• [1] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [4] Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int. 2007 Jul;100(1):51-7.
• [5] Inhaled Ciprofloxacin for the Management of Infections in Non-Cystic Fibrosis Bronchiectasis (BE) Patients
• [6] Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):171-9.
• [7] ClinicalTrials.gov (NCT01768663) A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
• [8] ClinicalTrials.gov (NCT00257699) Study of Antibiotics in the Treatment of Colonic Crohn's Disease
• [9] ClinicalTrials.gov (NCT04870138) Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
• [10] ClinicalTrials.gov (NCT03840811) Experimental Human Infection With Neisseria Gonorrhoeae
• [11] ClinicalTrials.gov (NCT02036528) Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers
• [12] ClinicalTrials.gov (NCT02773732) Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
• [13] ClinicalTrials.gov (NCT05232461) A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects
• [14] ClinicalTrials.gov (NCT05431673) Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma
• [15] ClinicalTrials.gov (NCT02015507) An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
• [16] ClinicalTrials.gov (NCT00002850) Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
• [17] ClinicalTrials.gov (NCT05294588) Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
• [18] ClinicalTrials.gov (NCT01783106) Antibiotics and Hydroxychloroquine in Crohn's
• [19] ClinicalTrials.gov (NCT02620007) Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
• [20] ClinicalTrials.gov (NCT04110340) Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
• [21] FDA Drug Development and Drug Interactions